GlassScriptPhysician profile
Deborah K Prather
NPI 1063690964
$6,141.63
in general payments reported to CMS, 2019-2025
43 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,019 · 2022: $1,178 · 2023: $1,721 · 2024: $1,018 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,944.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $896.25 | 2021 | |
| Abbvie INC. | $688.91 | 2021-2024 | |
| Novo Nordisk INC | $518.56 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $513.93 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $438.67 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $437.19 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $317.49 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.68 | 2021-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $251.26 | 2021-2023 | |
| Amgen INC. | $171.27 | 2022-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $148.19 | 2021-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $109.00 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.41 | 2021-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.80 | 2021-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $98.75 | 2021-2023 | Verquvo, Belsomra, Steglatro |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Prather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.